Clinical trials: Depressive
Bipolar I Depression
A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression
The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.
- Trial name
- NCT00812058
- Testing
- RG2417
- Where
- 36 sites in United States
- Volunteers
- 180 people
- Sponsor
- Repligen Corporation
Major Depressive Disorder
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication.
- Trial name
- NCT01380704
- Testing
- ABT-436
- Volunteers
- 51 people
- Sponsor
- AbbVie
Major Depressive Disorder
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder
The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).
- Trial name
- NCT02476058
- Testing
- JNJ-42847922, Diphenhydramine
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 48 people
- Sponsor
- Janssen-Cilag International NV
Bipolar Disorder, Bipolar Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a…
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- X-CEED (NCT07172516)
- Testing
- Azetukalner
- Where
- 44 sites in United States, Bulgaria and 2 more
- Volunteers
- 400 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response…
- Trial name
- NCT06633016
- Testing
- ABX-002
- Where
- 50 sites in United States
- Volunteers
- 230 people
- Sponsor
- Autobahn Therapeutics, Inc.
Depression in Remission
A Study of SDI-118 in Participants in Remission From Depression
This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting…
- Trial name
- NCT05212116
- Testing
- SDI-118
- Where
- 3 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Syndesi Therapeutics
Acute Depressive Episode
Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder
The purpose of this study is to determine the efficacy and safety of Ramelteon, once daily (QD), sublingual (SL), in adult participants with acute depressive episodes associated with Bipolar I disorder.
- Trial name
- NCT01467700
- Testing
- Ramelteon SL
- Where
- 161 sites in United States, Argentina and 3 more
- Volunteers
- 490 people
- Sponsor
- Takeda
Postpartum Depression
A Phase II Study of HS-10353 in Participants With Postpartum Depression
The primary purpose of this study is to determine if treatment with HS-10353 reduces depressive symptoms in participants with postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item…
- Trial name
- NCT05937867
- Testing
- HS-10353 Capsules 30 mg, Oral, QN for 14 days, HS-10353 Capsules 50 mg, Oral, QN for 14 days
- Volunteers
- 96 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00034944
- Testing
- MK0869, aprepitant
- Volunteers
- 495 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression, Depressive Disorder
Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
- Conditions
- Depression, Depressive Disorder, Major Depressive Disorder
- Trial name
- NCT00092911
- Testing
- DVS-233 SR
- Volunteers
- 244 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).
- Trial name
- NCT03002077
- Testing
- Rapastinel
- Where
- 128 sites in United States
- Volunteers
- 617 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder
The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.
- Trial name
- NCT00135421
- Testing
- Pexacerfont, Escitalopram
- Where
- 45 sites in United States
- Volunteers
- 271 people
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.
- Trial name
- NCT02067793
- Testing
- NRX-1074 1 mg, NRX-1074 5 mg, NRX-1074 10 mg
- Where
- 12 sites in United States
- Volunteers
- 151 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Depressive Disorder, Major
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms.
- Trial name
- RENEW-MDD- 2 (NCT07775300)
- Testing
- Brenipatide
- Where
- 170 sites in United States, Australia and 13 more
- Volunteers
- 1,000 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Treatment Resistant Major Depressive Disorder
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
To evaluate the efficacy and safety of AXS-05 relative to bupropion in subjects with treatment resistant major depressive disorder (MDD).
- Trial name
- STRIDE-1 (NCT02741791)
- Testing
- AXS-05, Bupropion
- Where
- 74 sites in United States
- Volunteers
- 312 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Premenstrual Dysphoric Disorder ( PMDD), PMDD
MLS101 Study in PMDD
The goal of this clinical trial is to learn if MLS101 (psilocybin) is a possible treatment for women with Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT07818720
- Testing
- MLS101 psilocybin
- Volunteers
- 32 people
- Sponsor
- MycoMedica Life Sciences PBC
Major Depressive Disorder
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT01273376)
- Testing
- RX-10100
- Where
- 44 sites in United States
- Volunteers
- 314 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.